Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

NAC has been seeking to get out from under $6.3bn (€5.8bn) of debt by handing itself to lenders. The restructuring plan involved an infusion of nearly $540m in new capital through a $337m equity ...